Biocon is a fully integrated biotechnology enterprise focused on the development of biopharmaceuticals. With its outstanding scientific knowledge pool, proprietary technologies and
world-class facilities, it is delivering “value differential” solutions to its partners and customers in more than 50 countries.

Biocon is committed to find biotechnology solutions for the patients of diabetes and cancer. On March 8th 2007, Biocon launched its Nephrology Division and a comprehensive range of renal therapy products. This Nephrology Division will find solution to kidney disorders through progressive research and new therapies. While doing this, it will use the highest standards of biotherapeutics.

The company is achieving excellence through:

  • Intellectual asset creation
  • State-of-art manufacturing capabilities

  • International benchmarks for the quality and regulatory systems
  • Disease-specific clinical research
  • Development of Human Resource through training, mentoring and empowerment

The company was founded on 29th November 1978. It has emerged from an enzyme manufacturing company to a fully integrated biopharmaceutical enterprise, which is focused on healthcare. It possesses a rare combination of proprietary fermentation technology and research skills.

In 1979 it became the first company to manufacture and export enzymes to USA and Europe. In 1996, the company’s proprietary fermentation plant had commercial success that led to 3-fold expansion. In 1998, the company became an independent entity when Unilever agreed to sell its shareholding in Biocon to the promoter.

In the year 2000, Clinigene, which is a subsidiary of Biocon, was set up to pursue clinical researches and developments. And in the year 2003, Biocon became the first company to develop human insulin on a Pichia expression system.

In 2004 it introduced new generation bio-insulin-INSUGEN. In 2006, Biocon launched India’s first cancer drug- BIOMAb EGFR.

Biocon together with Syngene and Clinigene has employee strength of about 2000, consisting of chemists, computer scientists, medical practitioners, engineers, chemists, market analysts and biologists.

Contact Us

Biocon: Biopharmaceuticals & Enzymes
Headquarters: Bangalore
20th KM Hosur Road
Electronics City
Bangalore 560 100
India
Ph: 91 80 2808 2808
Fax: 91 80 2852 3423
e-mail: contact.us@biocon.com

Quarterly Reports of Biocon

Quarterly Results (Rs. in Millions)
Dec 2006(3 rd quarter) Sept 2006(quarter 2nd) Dec 2005(3 rd quarter
Sales Turnover 2140.75 2191.06 1723.97
Other Income 22.69 10.46 19.88
Total Income 2163.44 2201.52 1743.86
Total Expenditure 1471.86 1651.37 1272.39
Operating Profit 691.58 550.15 471.46
Interest 19.33 18.45 3.68
Gross Profit 672.25 531.7 467.79
Depreciation 160.99 156.52 57.04
Tax 36.16 15.45 82.82
Reported PAT 475.1 359.74 327.93
Quarterly Results (in %)
% Change (Over Sep 2006) % Change (Over Dec 2005)
Sales Turnover -2.3 24.18
Other Income 116.89 14.12
Total Income -1.73 24.06
Total Expenditure -10.87 15.68
Operating Profit 25.71 46.69
Interest 4.8 426.07
Gross Profit 26.43 43.71
Depreciation 2.85 182.25
Tax
Reported PAT 32.07 44.88

Annual Unaudited Results (Rs. in Millions)
(12 Months) (12 Months) % Changes
Sales Turnover 6463.62 5018.82 28.79
Other Income 157.99 15.64 910.28
Total Income 6621.61 5034.46 31.53
Total Expenditure 4535.67 3405.45 33.19
Operating Profit 2085.94 1629.01 28.05
Interest 19.93 15.68 27.14
Gross Profit 2066.01 1613.33 28.06
Depreciation 180.92 138.53 30.6
Tax 141.22 228.08 -38.08
Reported PAT 1743.88 1246.73 39.88